

[LJ 827] OCTOBER 2016 Sub. Code: 3827

PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE) EGREE EXAMINATION (2009-2010 Regulation) FIFTH YEAR

PAPER III – CLINICAL PHARMACOKINETICS & HARMACOTHERAPEUTIC DRUG MONITORING

Q.P. Code: 383827

Time: Three hours Maximum: 70 Marks

I. Elaborate on: $(4 \times 10 = 40)$

1. Explain the pharmacokinetic changes and dose adjustment in Hepatic disease.

- 2. Enumerate the various methods of analyzing population pharmacokinetic data.
- 3. Explain the inhibition and induction of drug metabolism with example.
- 4. Explain the effect of Genetic Polymorphism in drug transport and drug target.

II. Write notes on: $(6 \times 5 = 30)$

- 1. Write a note on dosing in Pediatric patient.
- 2. Brief about the inhibition of Biliary excretion.
- 3. Write the factors to be considered when designing a dosage regimen.
- 4. Brief about the measurement of Glomerular Filtration Rate.
- 5. Brief about therapeutic drug monitoring of two Cardio Vascular drugs.
- 6. CYP2C19.
